These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 21823932)
1. Rapid and sustained resolution of serous retinal detachment in Sturge-Weber syndrome after single injection of intravitreal bevacizumab. Shoeibi N; Ahmadieh H; Abrishami M; Poorzand H Ocul Immunol Inflamm; 2011 Oct; 19(5):358-60. PubMed ID: 21823932 [TBL] [Abstract][Full Text] [Related]
2. Treatment of serous macular detachment associated with circumscribed choroidal hemangioma. Kwon HJ; Kim M; Lee CS; Lee SC Am J Ophthalmol; 2012 Jul; 154(1):137-145.e1. PubMed ID: 22465363 [TBL] [Abstract][Full Text] [Related]
3. [Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection]. Gregori-Gisbert I; Aguirre-Balsalobre F; García-Sánchez J; León-Salvatierra G; Mengual-Verdú E; Hueso-Abancéns JR Arch Soc Esp Oftalmol; 2011 Dec; 86(12):407-11. PubMed ID: 22117740 [TBL] [Abstract][Full Text] [Related]
4. Diffuse choroidal hemangioma associated with exudative retinal detachment in a Sturge-Weber syndrome case: photodynamic therapy and intravitreous bevacizumab. Anaya-Pava EJ; Saenz-Bocanegra CH; Flores-Trejo A; Castro-Santana NA Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):136-9. PubMed ID: 25560419 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. Aydin E J Ocul Pharmacol Ther; 2013 Feb; 29(1):10-3. PubMed ID: 22925113 [TBL] [Abstract][Full Text] [Related]
7. Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab. Barkmeier AJ; Kadikoy H; Holz ER; Carvounis PE Eur J Ophthalmol; 2011; 21(4):506-8. PubMed ID: 21240857 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418 [TBL] [Abstract][Full Text] [Related]
10. Treatment of persistent serous retinal detachment in Vogt-Koyanagi-Harada syndrome with intravitreal bevacizumab during the systemic steroid treatment. Reibaldi M; Russo A; Avitabile T; Uva MG; Franco L; Longo A; Toro MD; Cennamo G; Mariotti C; Neri P; Noci ND; Russo V Retina; 2014 Mar; 34(3):490-6. PubMed ID: 23903795 [TBL] [Abstract][Full Text] [Related]
11. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab. Lee ST; Adelman RA J Ocul Pharmacol Ther; 2011 Dec; 27(6):611-4. PubMed ID: 21810026 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma. Song JH; Bae JH; Rho MI; Lee SC Retina; 2010 Jun; 30(6):945-51. PubMed ID: 20531145 [TBL] [Abstract][Full Text] [Related]
13. [Patient with recurrent central serous chorioretinopathy who developed multiple evanescent white dots and serous retinal detachment immediately following bevacizumab administration]. Satoh S; Miyagawa Y; Mori T Nippon Ganka Gakkai Zasshi; 2012 Feb; 116(2):119-28. PubMed ID: 22509701 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for acute central serous chorioretinopathy. Kim M; Lee SC; Lee SJ Ophthalmologica; 2013; 229(3):152-7. PubMed ID: 23257663 [TBL] [Abstract][Full Text] [Related]
15. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity. Jonas JB; Tao Y; Rensch F J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013 [TBL] [Abstract][Full Text] [Related]
17. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Kim M; Lee P; Kim Y; Yu SY; Kwak HW Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]